Lymphatica Medtech SA, a clinical-stage company based in Lausanne specialising in new treatments for lymphedema, has raised €17.9 million in Series B funding. This investment will accelerate the clinical development and validation of LymphoDrain, a revolutionary implantable device designed to treat lymphedema, a chronic vascular disease that currently has no cure and affects millions of people worldwide.
Lymphatica was founded in July 2017 as a spin-off of EPFL Swiss Federal Institute of Technology Lausanne and the University Hospital of Lausanne CHUV. The company aims to become a leader in the development of innovative devices for the treatment of lymphatic diseases. The first of its kind, LymphoDrain is easy to implant subcutaneously using a minimally invasive technique and is designed to offer unprecedented benefits to patients by locally and actively replacing the drainage function of lymphatic vessels.
The round was co-led by Panakes Partners, TechWald Next S.p.A. and CDP Venture Capital’s Digital Transition Fund, with the participation of OCCIDENT, Zürcher Kantonalbank and the Business Angels of the Club Degli Investitori through Simon Fiduciaria. Existing investors, including High-Tech Gründerfonds (HTGF), also supported the round. To support its growth, Lymphatica has also opened a subsidiary in Italy, which will deal with business expansion, research and development, manufacturing and clinical operations.
Lymphatica is further strengthened with the appointment of Dan Rose as the new Chairman of the Board of Directors; Rose brings significant leadership experience from companies such as LimFlow (acquired by Inari Medical), Direct Flow Medical, Sequana Medical, and Medtronic. In addition, Alessio Beverina, Managing Partner of Panakes, and Lukas Guenther, Chief Investment Officer of TechWald Next, joined the Board of Directors alongside the current independent member of the Board of Directors Nanci Govinder.
Dr. Marco Pisano, CEO and co-founder of Lymphatica Medtech, said: “We are thrilled to have successfully closed our Series B funding round, which will allow us to advance the clinical development of our innovative technology for lymphedema patients. With the support of our investors and board members, we are one step closer to providing a transformative solution for patients suffering from lymphedema, significantly improving their quality of life.”
Valentina Triacca, COO and co-founder of Lymphatica Medtech, added: “Millions of people are living with chronic lymphedema and current treatment options do not offer adequate solutions. This investment allows us to continue developing LymphoDrain, our innovative device that has already shown promising results in a pilot feasibility study.”
Dan Rose, the company’s new Chairman of the Board, said: “Lymphatica has made impressive progress in developing compelling technology with the potential to transform care and improve the lives of the many lymphedema patients. It is a privilege to join the Board as President and support the efforts of this great team.”
Luca Porro and Alice Ravizza, Investors Club Champion in this round, said: “Lymphatica responds to a clear need of patients suffering from lymphedema in the arm or leg, proposing an innovative, simple and effective solution, potentially able to significantly improve the quality of life. We are excited to be able to support the startup in its clinical validation and regulatory approval journey.”
(Source: Club degli Investitori press release)
